Skip to content
value.today
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.

SPRO
$69 Mmarket cap on Oct 13, 2026-11.9% since Jan 2024
Compare
World rank
#20,150
Revenue
$67 M
For year ending December-2025
Net income
$9 M
12.8% margin
SEC filing
Employees
146
As on 2021
value.today research

Spero Therapeutics, Inc. in brief

Spero Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2013. Its market value was $69 M on 13 October 2026, which makes it the 20,150th largest listed company in the world and the 3,719th largest in the USA on this site. In the year to December 2025 it had sales of $67 M and a net profit of $9 M, about 13 cents of profit for every dollar of sales. It employs about 146 people. Its largest product and service lines by sales in 2025 were Collaboration revenue - related party (70%), Collaboration revenue (19%) and Grant Revenue (11%). Its shares trade under the symbol SPRO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Spero Therapeutics, Inc.

Spero Therapeutics is a Global, Multi Asset and Clinical Stage Biopharmaceutical company committed to advancing novel treatment approaches for bacterial infections. The company annual revenue is 9.3 million USD as on 2020. The headquarters is in USA.

Spero Therapeutics, Inc. timeline

5 events, 2013–2023
  1. 2013
  2. 🏁
    · approximate
    Founded
  3. 2017
  4. ✎
    Renamed Spero Therapeutics, Inc.
    Formerly Spero Therapeutics, LLC.
  5. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 2 November 2017; shares registered for exchange trading on 30 October 2017.
  7. 2023
  8. 💰
    Record revenue of $104 million
    FY2023, the highest of the 8 years on record.

Events of Spero Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$142 M$285 M$427 M$569 M2020202120222023202420252026

World rank over time

▼ down 4,108 places since 2020
2020-01-01: #16134#16,13420202021-01-01: #10905#10,90520212022-01-07: #14517#14,51720222022-12-25: #22716#22,71620222023-07-30: #23162#23,16220232024-01-05: #22678#22,67820242026-03-08: #9593#9,59320262026-08-01: #18366#18,36620262026-10-13: #20242#20,2422026

Rank in USA: #3,277 (Jan 2020) · #2,708 (Jan 2021) · #3,091 (Jan 2022) · #4,433 (Dec 2022) · #4,458 (Jul 2023) · #3,855 (Jan 2024) · #1,857 (Mar 2026) · #3,597 (Aug 2026) · #3,700 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
8.0×
Price / sales
1.0×
Price / book
1.2×
Free cash flow yield
-125.1%
Net margin
12.8%
Operating margin
9.4%
Return on equity
14.5%
Liabilities / assets
14.4%
Revenue growth
+39.2%
R&D / revenue
57.6%
Revenue per employee
$458 K
Profit per employee
$59 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $4M, net income $-42M$4MFY18Fiscal year ending Dec 2019: revenue $18M, net income $-61M$18MFY19Fiscal year ending Dec 2020: revenue $9M, net income $-78M$9MFY20Fiscal year ending Dec 2021: revenue $18M, net income $-90M$18MFY21Fiscal year ending Dec 2022: revenue $54M, net income $-46M$54MFY22Fiscal year ending Dec 2023: revenue $104M, net income $23M$104MFY23Fiscal year ending Dec 2024: revenue $48M, net income $-69M$48MFY24Fiscal year ending Dec 2025: revenue $67M, net income $9M$67MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$67M+39.2%$6M$9M12.8%
Dec 2024$48M-53.8%$-73M$-69M-142.9%
Dec 2023$104M+93.9%$21M$23M22.0%
Dec 2022$54M+193.0%$-42M$-46M-86.8%
Dec 2021$18M+95.7%$-88M$-90M-491.8%
Dec 2020$9M-48.6%$-79M$-78M-839.2%
Dec 2019$18M+357.2%$-63M$-61M-335.5%
Dec 2018$4M—$-43M$-42M-1050.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-13M——$0.15—
Dec 2024$-23M——$-1.27—
Dec 2023$-33M——$0.43—
Dec 2022$-8M——$-1.23—
Dec 2021$-64M——$-2.91—
Dec 2020$-86M$0M$-86M$-3.52—
Dec 2019$-50M$0M$-50M$-3.35—
Dec 2018$-40M$2M$-42M$-2.60—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $15M, net income $-21M$15MDec ’24Three months to Mar 2025: revenue $6M, net income $-14M$6MMar ’25Three months to Jun 2025: revenue $14M, net income $-2M$14MJun ’25Three months to Sep 2025: revenue $5M, net income $-7M$5MSep ’25Three months to Dec 2025 (from the annual report): revenue $41M, net income $32M$41MDec ’25Three months to Mar 2026: revenue $0M, net income $-7M$0MMar ’26Three months to Jun 2026: revenue —, net income $-10M—Jun ’26Three months to Sep 2026: revenue —, net income $-44M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-44M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Spero Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$67 M
Operating income
$6 M
Net income
$9 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$69 M
Total liabilities
$10 M
Total equity
$59 M

As of December-2025

Top 61 institutional investors in Spero Therapeutics, Inc.#

As of Sep 30, 2026
61 institutions held 25.8 M shares (about 44.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 36.8%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Spero Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1GSK plc9,190,6060 (0.00%)15.77%$11 MNov 5, 2026
2Pfizer Inc2,362,3480 (0.00%)4.05%$3 MNov 12, 2026
3Vanguard Capital Management LLC2,036,2260 (0.00%)3.49%$2 MNov 13, 2026
4Mackenzie Financial Corp1,831,254New3.14%$2 MNov 2, 2026
5Renaissance Technologies LLC1,409,783+461,879 (+48.73%)2.42%$2 MNov 12, 2026
6Affinity Asset Advisors, LLC1,300,000New2.23%$2 MNov 13, 2026
7Arrowstreet Capital, Limited Partnership997,123+664,153 (+199.46%)1.71%$1 MNov 13, 2026
8Verdad Advisers, LP805,702+754,367 (+1469.50%)1.38%$1 MNov 16, 2026
9Raymond James Financial Inc755,633+233,928 (+44.84%)1.30%$1 MNov 12, 2026
10Citadel Advisors LLC725,988New1.25%$1 MNov 16, 2026
11BlackRock, Inc.594,258-146 (-0.02%)1.02%$1 MNov 13, 2026
12Geode Capital Management, LLC499,271-67,058 (-11.84%)0.86%$1 MNov 6, 2026
13Vanguard Fiduciary Trust Co287,6480 (0.00%)0.49%$0 MNov 13, 2026
14Two Sigma Investments, LP267,195-115,619 (-30.20%)0.46%$0 MNov 16, 2026
15Morgan Stanley258,645+257,731 (+28198.14%)0.44%$0 MNov 13, 2026
16State Street Corp251,251+36,500 (+17.00%)0.43%$0 MNov 12, 2026
17HRT Financial LP204,964New0.35%$0 MNov 13, 2026
18Prudential Financial Inc204,663+194,263 (+1867.91%)0.35%$0 MNov 16, 2026
19Susquehanna International Group, LLP201,937-557,353 (-73.40%)0.35%$0 MNov 16, 2026
20Marshall Wace, LLP195,416New0.34%$0 MNov 13, 2026
21Shay Capital LLC166,030+93,639 (+129.35%)0.28%$0 MNov 16, 2026
22Invesco Ltd.165,530+101,285 (+157.65%)0.28%$0 MNov 12, 2026
23Employees Retirement System of Texas125,081New0.21%$0 MNov 10, 2026
24Northern Trust Corp108,2740 (0.00%)0.19%$0 MNov 16, 2026
25XTX Topco Ltd104,323+53,787 (+106.43%)0.18%$0 MNov 16, 2026
Show all 61: investors 26 to 61
Institutional investors 26 to 61 in Spero Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Squarepoint Ops LLC94,478New0.16%$0 MNov 9, 2026
27Dimensional Fund Advisors LP91,287-183,533 (-66.78%)0.16%$0 MNov 4, 2026
28Bridgeway Capital Management, LLC63,741-51,059 (-44.48%)0.11%$0 MNov 16, 2026
29Empowered Funds, LLC63,741New0.11%$0 MNov 13, 2026
30StoneX Group Inc.38,241New0.07%$0 MNov 3, 2026
31Simplex Trading, LLC36,830-24,482 (-39.93%)0.06%$0 MNov 4, 2026
32Panagora Asset Management Inc32,762New0.06%$0 MNov 12, 2026
33Two Sigma Securities, LLC32,684+22,108 (+209.04%)0.06%$0 MNov 16, 2026
34Capital Asset Advisory Services LLC32,5480 (0.00%)0.06%$0 MOct 30, 2026
35Three Seasons Wealth, LLC30,0000 (0.00%)0.05%$0 MNov 3, 2026
36Charles Schwab Investment Management Inc28,5650 (0.00%)0.05%$0 MNov 16, 2026
37Oppenheimer & Co Inc26,750+3,900 (+17.07%)0.05%$0 MOct 26, 2026
38Vanguard Global Advisers, LLC25,4460 (0.00%)0.04%$0 MNov 13, 2026
39FNY Investment Advisers, LLC21,300+13,000 (+156.63%)0.04%$0 MOct 16, 2026
40O'shaughnessy Asset Management, LLC20,704New0.04%$0 MNov 12, 2026
41Ritholtz Wealth Management20,704New0.04%$0 MNov 5, 2026
42Jane Street Group, LLC20,185-137,912 (-87.23%)0.03%$0 MNov 12, 2026
43Assenagon Asset Management S.A.17,762-19,510 (-52.34%)0.03%$0 MOct 15, 2026
44Rangeley Capital, LLC17,202New0.03%$0 MNov 16, 2026
45UBS Group AG16,049-123,631 (-88.51%)0.03%$0 MNov 10, 2026
46Point72 Asset Management, L.P.14,639-89,738 (-85.97%)0.03%$0 MNov 16, 2026
47Spark Investment Management LLC12,300New0.02%$0 MNov 13, 2026
48Vanguard Personalized Indexing Management, LLC11,571New0.02%$0 MNov 16, 2026
49Torrey Growth & Income Advisors11,025New0.02%$0 MNov 4, 2026
50Jones Financial Companies Lllp8,053+375 (+4.88%)0.01%$0 MNov 13, 2026
51Tower Research Capital LLC (TRC)6,838New0.01%$0 MNov 16, 2026
52Royal Bank Of Canada1,936-78 (-3.87%)0.00%$0 MNov 16, 2026
53FMR LLC1,100+800 (+266.67%)0.00%$0 MNov 10, 2026
54Osaic Holdings, Inc.2900 (0.00%)0.00%$0 MNov 12, 2026
55Jpmorgan Chase & Co2360 (0.00%)0.00%$0 MNov 12, 2026
56Wells Fargo & Company/mn2000 (0.00%)0.00%$0 MNov 16, 2026
57Nuveen, LLC177New0.00%$0 MNov 10, 2026
58US Bancorp \de\1510 (0.00%)0.00%$0 MNov 5, 2026
59SBI Securities Co., Ltd.61+48 (+369.23%)0.00%$0 MOct 22, 2026
60Farther Finance Advisors, LLC100 (0.00%)0.00%$0 MOct 8, 2026
61Barclays PLC6New0.00%$0 MNov 6, 2026

Mutual funds holding Spero Therapeutics, Inc.#

28 funds hold shares worth $7 M (about 5.3% of the company). Since their previous reports 19 added shares and 2 sold, buying $1 M net.
Mutual funds holding Spero Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.40 M$3 M2.4%<0.01%+13%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.593,254$1 M1.0%<0.01%+15%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC224,070$1 M0.38%<0.01%+8.0%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors151,203$0 M0.26%0.02%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC107,797$0 M0.19%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC67,356$0 M0.12%<0.01%+10%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC64,800$0 M0.11%0.10%no changeJun 30, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC56,457$0 M0.10%0.11%—Jun 30, 2026
🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC50,000$0 M0.09%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC36,745$0 M0.06%<0.01%+89%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP65,997$0 M0.11%<0.01%+314%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust22,770$0 M0.04%<0.01%newMay 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP46,660$0 M0.08%<0.01%newJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.24,176$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.22,820$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.28,565$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC26,957$0 M0.05%<0.01%+112%Jul 31, 2026
🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP25,054$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,170$0 M0.02%0.01%newJun 30, 2026
🇺🇸 U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP15,413$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP15,128$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP10,049$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP7,979$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP7,963$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,961$0 M<0.01%<0.01%+6.4%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP4,874$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP4,833$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC2,400$0 M<0.01%<0.01%−59%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 28 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Spero Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$499 K
9 sales, 2 insiders
Net, 12 months
-$499 K
open market only
Insiders on file
23
since
-$393 K$0Feb 2024: bought $0 (0 trades), sold $318 K (6 trades)Feb 24Aug 2024: bought $0 (0 trades), sold $57 K (5 trades)Nov 2024: bought $0 (0 trades), sold $53 K (2 trades)NovFeb 2025: bought $0 (0 trades), sold $235 K (9 trades)Aug 2025: bought $0 (0 trades), sold $16 K (2 trades)AugNov 2025: bought $0 (0 trades), sold $95 K (1 trades)Feb 2026: bought $0 (0 trades), sold $393 K (7 trades)FebMay 2026: bought $0 (0 trades), sold $63 K (1 trades)Nov 2026: bought $0 (0 trades), sold $42 K (1 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Spero Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Esther RajaveluSee Remarks, DirectorSell-40,851$1.040$42 K946,000Form 4
filed Debra ZackChief Medical OfficerGrant or award10b5-1 plan+162,311——162,311Form 4
filed Scott Thomas JacksonDirectorGrant or award+10,000——85,000Form 4
filed Milind DeshpandeDirectorGrant or award+10,000——101,454Form 4
filed John C. Pottage Jr.DirectorGrant or award+10,000——85,000Form 4
filed Cynthia SmithDirectorGrant or award+10,000——85,000Form 4
filed Kathleen TregoningDirectorGrant or award+10,000——85,000Form 4
filed Patrick V.j.j. VinkDirectorGrant or award+10,000——85,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Spero Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
787,025
1.4% of shares · 2.23 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-05-28 16:07 UTC, code LUDP, resumed 16:12 UTC
  • 2025-05-28 15:18 UTC, code LUDP, resumed 15:23 UTC
  • 2025-05-28 14:54 UTC, code LUDP, resumed 14:59 UTC
  • 2025-05-28 14:46 UTC, code LUDP, resumed 14:51 UTC
  • 2025-05-28 13:46 UTC, code LUDP, resumed 13:51 UTC

Fails to deliver

  • : 1,111 shares at $1.18
  • : 50,000 shares at $1.26
  • : 15,213 shares at $1.22
  • : 17 shares at $1.23
  • : 742 shares at $1.23

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Spero Therapeutics, Inc. scorecard#

Passes 14 of the 20 checks that could be worked out: strongest in growth (5 of 6), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 13, 2026.

  • Valuation4 of 5
    • ✓P/E below its peers' median8.0×P/E 8.0× against Biotechnology's median of 17.5×.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-125.1%Free cash flow is -125.1% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield12.5%Earnings yield 12.5% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth5 of 6
    • ✓Revenue grew in the newest year39.2%Revenue up 39.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years7.7%7.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median7.7%7.7% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year0.15 vs -1.27Diluted EPS 0.15 in fiscal 2025 against -1.27 the year before (report's currency).
    • ✓Net income higher than five years earlier$9 M$9 M in fiscal 2025 against -$78 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability4 of 5
    • ✓Profitable in the newest year$9 MNet income $9 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median9.4%9.4% against Biotechnology's median of -60.5% (243 companies).
    • ✓Return on equity above 15%16.3%16.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier9.4%9.4% in fiscal 2025 against -78.9% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities7.6×Current ratio 7.59 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-2.71Z-score -2.71 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year9.2%Diluted shares up 9.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Spero Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Spero Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin9.5%-60.5%
Net margin12.8%-68.9%
Return on equity16.3%-61.0%
Revenue growth, 3 years a year7.7%12.9%
Revenue growth39.2%15.8%

4of 7on the Piotroski tests of financial strength

  • Only -147% of net income arrived as cash from operations.
  • The share count rose 9.2% in the year.

Spero Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Spero Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue674810454189.3184.02.00.3
Research and development38975148656766343326
General and administrative2124263642211613117.2
Operating expenses6012182961068881474434
Operating income6.3−7321−42−88−79−63−43−42−33
Interest and finance income2.54.73.91.10.30.41.31.1——
Other non-operating income (expense)2.54.83.9−4.2−1.80.82.31.11.80.6
Income before tax8.8−6925−46−90−78−61−42−40−33
Income tax0.302.60000000
Net income including minority interests8.6−6923−46−90−78−61−42−40−33
Minority interests' share of net income————————−1.1−7.2
Net income attributable to shareholders8.6−6923—−90−78−61−42r−39−25
Earnings per share, basic0.15-1.270.43-1.23-2.91-3.52-3.35-2.60-17.82-95.87
Earnings per share, diluted0.15-1.270.43-1.23-2.91-3.52-3.35-2.60-17.82-95.87
Shares, weighted average (basic)5654533831—————
Shares, weighted average (diluted)59545338312218162.60.3
Balance sheet
Cash and cash equivalents4053761091138530348710
Short-term investments———034425281——
Other current assets0.0r1.94.23.48.86.14.87.51.81.3
Current assets67107131114158139951249212
Property, plant and equipment—00.00.41.01.72.32.91.21.5
Right-of-use (leased) assets1.53.14.25.16.57.14.9———
Total assets691111821251711531061299314
Accounts payable0.77.31.40.61.11.24.13.63.51.1
Current liabilities8.9493722191427128.26.9
Lease liabilities (non-current)0.92.63.85.06.06.94.6———
Total liabilities9.9647549832132138.57.4
Retained earnings−451−460−391−414−367−278−199−139−97−45
Shareholders' equity594610776881327511685−45
Minority interests———————0.40.4−3.8
Total equity—————1327511685−49
Total liabilities and equity691111821251711531061299314
Shares outstanding565553523229191714—
Cash-flow statement
Depreciation and amortization00.00.40.90.60.80.80.40.40.3
Share-based compensation4.37.87.99.19.44.93.82.71.40.2
Cash from operating activities−13−23−33−7.7−64−86−50−40−39−29
Capital expenditure—————−0.2−0.3−2.4−0.0−0.8
Cash from investing activities——0347.71030−83−0.0−0.8
Shares issued—00.2—7.81316———
Cash from financing activities—00.2−3084131167011634
Change in cash−13−23−33−3.52755−4.4−53774.6
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Spero Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Collaboration revenue - related party$47 M70%
  • Collaboration revenue$13 M19%
  • Grant Revenue$7 M11%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Spero Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.1 M
Ms. Rajavelu, Mr. Shukla
Other top executives, average
$1.4 M
the CEO earned 1.4× this
$100 invested is now
$12
Spero Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Ms. Rajavelu, Mr. Shukla$2.1 M$3.3 M$1.4 M$12
2024Mr. Shukla$2.0 M$2.2 M$945 K$5
2023Mr. Shukla$2.4 M$2.6 M$1.4 M$8

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Spero Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Restructuring 1 · Directors and officers 8 · Material agreement 2 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13

Spero Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Material agreementNew debt8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Directors and officersResults announced8-K
Results announced8-K
RestructuringResults announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Spero Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$9 MPrivate placement after listing$2 to $10 million1equitySEC
Jun 2021$40 MPrivate placement after listing$10 to $50 million1equitySEC
Mar 2017$43 MNo. 1$10 to $50 million11equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Spero Therapeutics, Inc.#

$70 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues.

Lobbying, 2022
$70 K
#1,208 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Health Issues2 reports

Lobbying firms hired in 2022

Forbes-Tate $70 K

Spero Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$70 K—2
2021$50 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Spero Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Spero Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2020 for 2 positions, at a median wage of $128 K a year.

Certified, FY2020
2
#1,561 among companies on value.today
Worker positions
2
Median wage offered
$128 K
a year, full-time
Applications filed
2
Spero Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2020
Job titlePositionsMedian wage offered
Bioanalytical and DMPK ManagerBiochemists and Biophysicists1$129 K
Manager, Analytical DevelopmentBiochemists and Biophysicists1$127 K

Where: Cambridge, MA 2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Spero Therapeutics, Inc.

Layoffs at Spero Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2022–2024
Latest
—
2024-10-29
Spero Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
2022············—
Spero Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
39% of workforceRestructuring planSEC 8-K“Item 2.05 Costs Associated with Exit or Disposal Activities On October 29, 2024, the Company announced an update to its strategic priorities and corresponding reduction in workforc…”Filing
75% of workforceRestructuring planSEC 8-K“In connection with this development, Spero announced that it is undertaking a reduction in its workforce by approximately 75% and a restructuring of its operations to reduce operat…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Spero Therapeutics, Inc. compares in Biotechnology

  • Market cap$69 M · higher than 31% of 726
  • Revenue$67 M · higher than 63% of 647
  • Net margin12.8% · higher than 80% of 408
  • Revenue growth39.2% · higher than 70% of 438
  • P/E ratio8.0× · lower than 78% of 100
  • Price / sales1.0× · lower than 93% of 339
  • Price / book1.2× · lower than 76% of 534
  • FCF yield-125.1% · higher than 7% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Spero Therapeutics, Inc.🇺🇸$69 M8.0×12.8%+39.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 13, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Spero Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Spero Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Spero Therapeutics, Inc.? Suggest a correction